SubsidieMeestersSmart Implant for Magnetic Anastomotic Healing and Leakage Evaluation
The SMARTHEAL project aims to develop a smart magnetic anastomosis implant with integrated micro-sensors for enhanced healing and early detection of leaks, improving surgical outcomes and reducing costs.
Projectdetails
Introduction
Colorectal cancer affects over 1.93 million people worldwide each year. In most cases, surgery to remove the tumour is necessary, and intestinal continuity is restored through an anastomosis. However, a serious complication, known as an anastomotic leak, occurs in up to 20% of procedures.
Complications of Anastomotic Leaks
This complication is associated with:
- High mortality rates
- Frequent re-interventions
- Prolonged hospital stays
- Increased healthcare costs
- Reduced quality of life
Despite decades of research, the incidence of anastomotic leaks remains high, largely due to poor healing and delayed recognition.
Project Overview
Leveraging outcomes from the FET Open project '5D NanoPrinting' and EIC Project 'IV-Lab', Trinity College Dublin and the Istituto Italiano di Tecnologia, in collaboration with Plio Surgical and Amsterdam UMC, aim to integrate the results of micro-sensor and nano-printing technologies into a disruptive smart magnetic anastomosis implant.
Features of the Innovative Implant
This innovative implant will offer:
- Healing capabilities
- Sensing capabilities
It will monitor physical and chemical parameters that signal inflammation and edema at the anastomosis site.
Advancement of Technology
The SMARTHEAL project will advance this technology from TRL 3 to TRL 6 by embedding micro-sensors within the implant to detect key markers of anastomotic leaks. These sensors will be integrated with wireless electronics to transmit real-time data on healing biomarkers, with the implant's accuracy demonstrated in pre-clinical models.
Significance of SMARTHEAL
SMARTHEAL represents a groundbreaking advancement, being the first implant to simultaneously enhance healing and enable early leak detection. This innovation has the potential to significantly improve surgical outcomes and reduce healthcare costs globally.
Commercial Opportunity
It offers a substantial commercial opportunity for Plio Surgical, which aims to undertake the clinical and regulatory activities to bring this technology to market.
Financiële details & Tijdlijn
Financiële details
| Subsidiebedrag | € 2.499.815 |
| Totale projectbegroting | € 2.499.815 |
Tijdlijn
| Startdatum | 1-5-2025 |
| Einddatum | 31-10-2027 |
| Subsidiejaar | 2025 |
Partners & Locaties
Projectpartners
- THE PROVOST, FELLOWS, FOUNDATION SCHOLARS & THE OTHER MEMBERS OF BOARD, OF THE COLLEGE OF THE HOLY & UNDIVIDED TRINITY OF QUEEN ELIZABETH NEAR DUBLINpenvoerder
- FONDAZIONE ISTITUTO ITALIANO DI TECNOLOGIA
- PLIO SURGICAL LIMITED
- STICHTING AMSTERDAM UMC
Land(en)
Vergelijkbare projecten binnen EIC Transition
| Project | Regeling | Bedrag | Jaar | Actie |
|---|---|---|---|---|
Targeting cardiac fibrosis with next generation RNA therapeuticsFIBREX aims to develop an innovative ncRNA-based antisense oligonucleotide therapy targeting Meg3 to reverse cardiac fibrosis and treat heart failure, advancing towards clinical readiness. | EIC Transition | € 2.499.482 | 2022 | Details |
automated in-line separatioN and dEtection of eXtracellular vesicles for liqUid biopsy applicationSThe NEXUS project aims to industrialize a customizable platform for the separation and analysis of extracellular vesicles from biofluids, enhancing cancer diagnostics and monitoring. | EIC Transition | € 2.497.750 | 2022 | Details |
Predictive REagent-Antibody Replacement Technology stage 2-TranslationPRe-ART-2T aims to advance predictive antibody technology to TRL6, replacing low-quality monoclonal antibodies with high-performing synthetic alternatives, and attract ~€20M in investment. | EIC Transition | € 800.000 | 2022 | Details |
Advancing a vaccine targeting genetic amyotrophic lateral sclerosis (C9orf72 ALS) to the clinical stageDeveloping a poly-GA peptide vaccine to reduce protein aggregation and motor deficits in C9orf72 ALS, aiming for clinical evaluation and market entry through strategic partnerships. | EIC Transition | € 2.499.810 | 2022 | Details |
Targeting cardiac fibrosis with next generation RNA therapeutics
FIBREX aims to develop an innovative ncRNA-based antisense oligonucleotide therapy targeting Meg3 to reverse cardiac fibrosis and treat heart failure, advancing towards clinical readiness.
automated in-line separatioN and dEtection of eXtracellular vesicles for liqUid biopsy applicationS
The NEXUS project aims to industrialize a customizable platform for the separation and analysis of extracellular vesicles from biofluids, enhancing cancer diagnostics and monitoring.
Predictive REagent-Antibody Replacement Technology stage 2-Translation
PRe-ART-2T aims to advance predictive antibody technology to TRL6, replacing low-quality monoclonal antibodies with high-performing synthetic alternatives, and attract ~€20M in investment.
Advancing a vaccine targeting genetic amyotrophic lateral sclerosis (C9orf72 ALS) to the clinical stage
Developing a poly-GA peptide vaccine to reduce protein aggregation and motor deficits in C9orf72 ALS, aiming for clinical evaluation and market entry through strategic partnerships.
Vergelijkbare projecten uit andere regelingen
| Project | Regeling | Bedrag | Jaar | Actie |
|---|---|---|---|---|
Smart 4D biodegradable metallic shape-shifting implants for dynamic tissue restorationBIOMET4D aims to revolutionize reconstructive surgery with shape-morphing implants for dynamic tissue restoration, enhancing regeneration while reducing costs and invasiveness. | EIC Pathfinder | € 4.039.541 | 2022 | Details |
Smart manufacturing for autologous cell therapies enabled by innovative biomonitoring technologies and advanced process controlThe SMARTER project aims to develop a smart bioprocessing platform for personalized autologous cell therapies, enhancing manufacturing efficiency and enabling clinical use for solid tumors. | EIC Pathfinder | € 1.364.281 | 2022 | Details |
Multi-sensor Eversion Robot Towards Intelligent Endoscopic Diagnosis and TherapyEndoTheranostics aims to revolutionize colorectal cancer screening and treatment through a robotic system that enables painless preparation, real-time polyp detection, and effective removal using advanced imaging and tools. | ERC SyG | € 7.616.426 | 2024 | Details |
Implican StaplerImplican BV ontwikkelt een innovatief apparaat om naadlekkage na darmchirurgie te voorkomen door primaire wondgenezing te bevorderen, met als doel sneller herstel en lagere zorgkosten. | MIT Haalbaarheid | € 20.000 | 2020 | Details |
Smart 4D biodegradable metallic shape-shifting implants for dynamic tissue restoration
BIOMET4D aims to revolutionize reconstructive surgery with shape-morphing implants for dynamic tissue restoration, enhancing regeneration while reducing costs and invasiveness.
Smart manufacturing for autologous cell therapies enabled by innovative biomonitoring technologies and advanced process control
The SMARTER project aims to develop a smart bioprocessing platform for personalized autologous cell therapies, enhancing manufacturing efficiency and enabling clinical use for solid tumors.
Multi-sensor Eversion Robot Towards Intelligent Endoscopic Diagnosis and Therapy
EndoTheranostics aims to revolutionize colorectal cancer screening and treatment through a robotic system that enables painless preparation, real-time polyp detection, and effective removal using advanced imaging and tools.
Implican Stapler
Implican BV ontwikkelt een innovatief apparaat om naadlekkage na darmchirurgie te voorkomen door primaire wondgenezing te bevorderen, met als doel sneller herstel en lagere zorgkosten.